Online inquiry

IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14228MR)

This product GTTS-WQ14228MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14228MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9163MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ14986MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ14206MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ6377MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ9313MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ16014MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ14352MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ601MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW